BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

59 related articles for article (PubMed ID: 15734947)

  • 1. New opportunities for dosimetric approach in patients with differentiated thyroid cancer.
    Piscopo L; Zampella E; Klain M
    Eur J Nucl Med Mol Imaging; 2024 Jan; 51(2):330-331. PubMed ID: 37870586
    [No Abstract]   [Full Text] [Related]  

  • 2. The combined evaluation of clinical and biochemical data in management of patients with differentiated thyroid cancer.
    Volpe F; Piscopo L
    Eur J Nucl Med Mol Imaging; 2023 Dec; 51(1):230-232. PubMed ID: 37552368
    [No Abstract]   [Full Text] [Related]  

  • 3. 131I therapeutic efficacy is not influenced by stunning after diagnostic whole-body scanning.
    Dam HQ; Kim SM; Lin HC; Intenzo CM
    Radiology; 2004 Aug; 232(2):527-33. PubMed ID: 15286323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differentiated thyroid carcinoma: Incremental diagnostic value of
    Zilioli V; Peli A; Panarotto MB; Magri G; Alkraisheh A; Wiefels C; Rodella C; Giubbini R
    Endocrine; 2017 Jun; 56(3):551-559. PubMed ID: 27709475
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of scanning doses of iodine-131 on subsequent first ablative treatment outcome in patients operated on for differentiated thyroid carcinoma.
    Muratet JP; Daver A; Minier JF; Larra F
    J Nucl Med; 1998 Sep; 39(9):1546-50. PubMed ID: 9744340
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Self-stunning in thyroid ablation: evidence from comparative studies of diagnostic 131I and 123I.
    Hilditch TE; Dempsey MF; Bolster AA; McMenemin RM; Reed NS
    Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):783-8. PubMed ID: 12029552
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stunning with 131I diagnostic whole-body imaging of patients with thyroid cancer.
    Gerard SK; Dam HQ
    Radiology; 2005 Mar; 234(3):972-3; author reply 973-4. PubMed ID: 15734947
    [No Abstract]   [Full Text] [Related]  

  • 8. [Follow-up of children and young adults with differentiated thyroid cancer treated with radioiodine].
    Coronado Poggio M; Martin Curto LM; Marín Ferrer MD; Coya Viña J; Couto Caro RM; Navarro Martínez T; Riesco Almarza G
    Rev Esp Med Nucl; 2003; 22(5):316-26. PubMed ID: 14534007
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radioiodine therapy for papillary and follicular thyroid carcinoma.
    Klain M; Ricard M; Leboulleux S; Baudin E; Schlumberger M
    Eur J Nucl Med Mol Imaging; 2002 Aug; 29 Suppl 2():S479-85. PubMed ID: 12192549
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Differentiated thyroid cancers].
    Gorgone S; Campennì A; Calbo E; Catalfamo A; Sciglitano P; Sofia L; Niceta M; Borzì R; Calbo L
    G Chir; 2009; 30(1-2):26-9. PubMed ID: 19272228
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Follow-up of differentiated thyroid cancer.
    Pacini F
    Eur J Nucl Med Mol Imaging; 2002 Aug; 29 Suppl 2():S492-6. PubMed ID: 12192551
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.